نتایج جستجو برای: her2 receptors

تعداد نتایج: 236775  

2017
Anna M. Serwotka-Suszczak Alicja M. Sochaj-Gregorczyk Jerzy Pieczykolan Daniel Krowarsch Filip Jelen Jacek Otlewski

Antibody-drug conjugates (ADCs) have recently emerged as efficient and selective cancer treatment therapeutics. Currently, alternative forms of drug carriers that can replace monoclonal antibodies are under intensive investigation. Here, a cytotoxic conjugate of an anti-HER2 (Human Epidermal Growth Factor Receptor 2) diaffibody with monomethyl-auristatin E (MMAE) is proposed as a potential anti...

Journal: :Endocrine-related cancer 2005
W F Symmans D J Fiterman S K Anderson M Ayers R Rouzier V Dunmire J Stec V Valero N Sneige C Albarracin Y Wu J S Ross P Wagner R L Theriault B Arun H Kuerer K R Hess W Zhang G N Hortobagyi L Pusztai

The pathogenesis of breast cancers that do not express estrogen receptors or Her-2/neu receptors (ER-/HER2- phenotype) is incompletely understood. We had observed markedly elevated gene expression of gamma-aminobutyric acid type A (GABA(A)) receptor subunit pi (GABApi, GABRP) in some breast cancers with ER-/HER2- phenotype. In this study, transcriptional profiles (TxPs) were obtained from 82 pr...

Journal: :Asian Pacific journal of cancer prevention : APJCP 2014
Mohamad Nidal Khabaz

In Saudi Arabia, cancer of breast is ranked the most frequent neoplasm and second source of cancer death in the female population. Breast cancer (BC) fast diagnosis, prognosis and medication management necessitate, these days, immunohistochemistry (IHC) assessment of hormone receptors and HER2 expression profile. The present report defines the IHC profile of ER, PR and HER2 in Saudi female brea...

2013
Brent N. Rexer Ritwik Ghosh Archana Narasanna Valeria Estrada Anindita Chakrabarty Youngchul Song Jeffrey A. Engelman Carlos L. Arteaga

Purpose: Mutations in receptor tyrosine kinase (RTK) genes can confer resistance to receptor-targeted therapies. A T798M mutation in the HER2 oncogene has been shown to confer resistance to the tyrosine kinase inhibitor (TKI) lapatinib. We studied the mechanisms of HER2-T798M–induced resistance to identify potential strategies to overcome that resistance. Experimental Design:HER2-T798Mwas stabl...

2018
Alexey A. Larionov

The median survival of patients with human epidermal growth factor receptor 2 (HER2)positive metastatic breast cancer (MBC) has more than doubled, since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 years in 2017. The initial generation of HER2-targeted therapies included trastuzumab with taxanes in the first...

2012
Rita Nahta

The past decade of research into HER2-overexpressing breast cancer has provided significant insight into the mechanisms by which HER2 signaling drives tumor progression, as well as potential mechanisms by which cancer cells escape the anticancer activity of HER2-targeted therapy. Many of these preclinical findings have been translated into clinical development, resulting in novel combinations o...

Journal: :International journal of oncology 2015
Hao Liu Johan Seijsing Fredrik Y Frejd Vladimir Tolmachev Torbjörn Gräslund

Development of cancer treatment regimens including immunotoxins is partly hampered by their immunogenicity. Recently, deimmunized versions of toxins have been described, potentially being better suited for translation to the clinic. In this study, a recombinant tripartite fusion toxin consisting of a deimmunized version of exotoxin A from Pseudomonas aeruginosa (PE38) genetically fused to an af...

Journal: :Cancer research 2014
Sweta Rani Claire Corcoran Liam Shiels Serena Germano Susan Breslin Stephen Madden Martina S McDermott Brigid C Browne Norma O'Donovan John Crown Martina Gogarty Annette T Byrne Lorraine O'Driscoll

Intrinsic and acquired resistance to HER-targeting drugs occurs in a significant proportion of HER2-overexpressing breast cancers. Thus, there remains a need to identify predictive biomarkers that could improve patient selection and circumvent these types of drug resistance. Here, we report the identification of neuromedin U (NmU) as an extracellular biomarker in cells resistant to HER-targeted...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2005
Christopher W Gregory Young E Whang Wesley McCall Xiaoyin Fei Yuanbo Liu Liliana A Ponguta Frank S French Elizabeth M Wilson H Shelton Earp

PURPOSE The androgen receptor (AR) is a ligand-dependent transcription factor that mediates gene expression and growth of normal and malignant prostate cells. In prostate tumors that recur after androgen withdrawal, the AR is highly expressed and transcriptionally active in the absence of testicular androgens. In these "androgen-independent" tumors, alternative means of AR activation have been ...

2007

COPYRIGHT © 2007 NEW MEDICINE INC. UNAUTHORIZED PHOTOCOPYING, DISTRIBUTION OR ELECTRONIC STORAGE IS PROHIBITED BY LAW. THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY IN CANCER PART II — TARGET CANCER INDICATIONS AND TARGETING APPROACHES ERBB RECEPTORS ASSOCIATION BY CANCER INDICATION 1958 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) 1959 Colorectal Cancer 1959 Head and Neck Cancer 1960 Lung Can...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید